Long-term study of elafibranor for primary biliary cholangitis
Part of Digestive system clinical trials.
This trial tests a drug called elafibranor for people with primary biliary cholangitis (PBC), a liver disease. It aims to see if the drug is safe and works well over a long time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a diagnosis of primary biliary cholangitis (PBC).
- You have cirrhosis and are at a stable stage (Child Pugh A or B).
- You have not taken certain liver-related medications in the past 3 months.
- You do not have other serious liver diseases or complications.
- You agree to use contraception if needed and follow study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether fenofibrate, a medicine that lowers fats in the blood, can help people with primary biliary cholangitis (a chronic liver disease) who haven't had treatment before. It aims to see if it is safe and effective as a first treatment option.
This study tests fenofibrate, a medicine that may help lower liver enzymes in people with primary biliary cholangitis (PBC). It looks at how well the drug works in everyday medical practice.
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
This trial is testing whether adding fenofibrate to the standard PBC medicine ursodeoxycholic acid helps people with primary biliary cholangitis. It's a real-world study, meaning it looks at how treatments work in everyday practice. You can join only if you have already completed an earlier fenofibrate study.
This trial tests adding prednisone (a steroid) to ursodeoxycholic acid (a bile acid medicine) for people with primary biliary cholangitis who have a specific type of liver inflammation. The goal is to see if the combination works better at controlling the disease than standard care.
This trial tests a program of exercise, nutrition, and education to help reduce fatigue in people with primary biliary cholangitis. It aims to see if this program can improve energy and quality of life.
Hear when a new Primary Biliary Cholangitis (PBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.